Merck said on Monday it has raised its outlook for new growth drivers, forecasting $70 billion in revenue from these fresh ...
Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...
The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025–2034), mainly attributed to the launch of upcoming therapies such as ...
The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...
Half of the net proceeds will go to Jazz; it remains unclear who will get the remaining sum. Jazz did not reveal the buyer of ...
Merck Still Wants to "Grow Through Keytruda," Expects $70B in Revenue From New Programs by Mid-2030s
At the JP Morgan Healthcare Conference, the firm highlighted two antibody-drug conjugates among 10 programs that will fuel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback